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Economic analyses of genetic tests in personalized medicine: 
clinical utility first, then cost utility
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In the current issue of Genetics in Medicine, Phillips et al.1 report a thorough systematic 
review of published cost-utility analyses (CUAs) of clinical molecular genetic tests, or 
personalized medicine tests as the authors refer to them. By analyzing the Tufts Cost-
Effectiveness Analysis Registry, the authors identified 59 CUAs published from 1995 
through to 2011 that were considered to fulfill the study criteria. One of those, however, 
evaluated the use of a biomarker, transferrin saturation, to test for hereditary 
hemochromatosis and was published in 1995,2 before the discovery of HFE in 1996. All the 
studies in the Cost-Effectiveness Analysis Registry use quality-adjusted life-years (QALYs) 
as the metric of health outcomes. The Cost-Effectiveness Analysis Registry is a 
comprehensive database of published CUAs that lends itself to systematic reviews with a 
high degree of completeness of coverage. The Cost-Effectiveness Analysis Registry has 
been used in numerous published analyses to study the evolution of economic evaluation in 
various areas of health, but this is the first analysis of the registry to focus on genomic or 
personalized medicine. Previous systematic reviews on economic evaluations of genetic 
testing have included other methods of economic evaluations in addition to CUA but may 
have had lesser sensitivity in identifying relevant publications.
The authors report that 20% (n = 12) of the 59 CUA studies in their sample (including a 
CUA of phenotypic cascade screening for hemochromatosis)2 reported negative incremental 
direct medical costs, i.e., cost saving. This is similar to the fraction of clinical preventive 
services recommended by the US Preventive Services Task Force calculated to be cost 
saving.3 An additional 60% of incremental cost-effectiveness ratios (ICERs) were positive, 
i.e., not cost saving, and less than US$100,000 per QALY, a threshold for assessing the cost 
effectiveness commonly cited in the US publications.
Phillips et al.1 acknowledge a lack of consensus for a single threshold for ICERs and 
therefore report estimates for two thresholds, US $50,000 and US $100,000 per QALY. 
Whether any fixed ICER threshold makes sense as a decision rule is debatable,4 but even 
without a decision rule, an ICER can inform assessments of the value of interventions. 
Before comparing ICER estimates from different years, one should adjust for differences in 
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purchasing power resulting from price inflation. Without adjusting for inflation, a fixed 
ICER threshold will classify more estimates from older studies as cost effective relative to 
recent estimates.
Despite the most favorable findings of the cost-utility analyses summarized by Phillips et 
al.,1 the authors were appropriately careful not to make generalizations about the cost 
effectiveness of genetic tests in personalized medicine. They noted that just 6 of the 59 tests 
reviewed were classified by the Centers for Disease Control and Prevention as supported by 
evidence-based recommendations from groups such as the Evaluation of Genomic 
Applications in Practice and Prevention Working Group (EWG), the US Preventive Services 
Task Force, and the National Institute of Health and Clinical Excellence in England. The 
other 53 tests may or may not have adequate evidence of effectiveness. This is a crucial 
point, because, as has been noted by Conti et al.,5 without evidence of effectiveness, there 
can be no cost effectiveness. One can have superb modeling with a moderate or high score 
on a quality assessment for economic evaluations, but if the underlying data needed to 
quantify incremental health outcomes are inconclusive, conclusions about cost effectiveness 
should be treated with caution.
Phillips et al.1 state that all the six tests defined by the Centers for Disease Control and 
Prevention as having demonstrated clinical utility, i.e., tier 1 genomic applications with 
evidence-based recommendations, had CUA estimates. Clinical utility means net benefit to 
patients, i.e., positive patient outcomes (benefits) are expected to exceed negative patient 
outcomes (harms). A test per se does not have clinical utility apart from a clinical 
application. In particular, one of the six tests cited by Phillips et al.1 is testing for Lynch 
syndrome, recommended by the EWG.6 As Table 2 in their study makes clear, the EWG 
endorsement is specific to “screening newly diagnosed cases of colorectal cancer for Lynch 
syndrome and cascade testing of relatives of affected Lynch syndrome cases.” Cost-utility 
estimates were available for a different Lynch syndrome testing strategy, one in which 
unselected adults unaffected by cancer would be offered gene sequencing based on the 
knowledge of their family history.7 This testing approach, which presumes the hypothetical 
availability of cost-free and perfectly reliable family history information in a primary-care 
setting, is not a tier 1 application with an evidence-based recommendation.
Two cost-effectiveness analyses of the Lynch syndrome testing approach endorsed by the 
EWG were published during the study period.8,9 Both reported that universal testing of 
newly diagnosed colorectal cancer patients is likely to cost less than US $50,000 per life-
year saved, although the two studies differed with respect to the numbers of family members 
that would have to be tested per proband for testing to be considered cost effective at that 
threshold. The cost-effectiveness ranking of interventions that reduce premature death is 
typically unaffected if one uses life-years saved in place of QALYs.10
The most common disease area among the 59 CUAs is cancer (n = 23), followed by 
infectious disease (n = 9), coagulation (n = 8), and mental health (n = 4). Five of the 
coagulation CUAs evaluated genetic testing for thrombophilias such as the factor V Leiden 
variant on F5 and prothrombin 20210G>A variant on F2, and three CUA-assessed 
pharmacogenetic testing for warfarin dosing. None of these studies evaluated a test with 
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demonstrated clinical utility as defined by Phillips et al.1 Indeed, the EWG recommends 
against testing patients with idiopathic venous thromboembolism for factor V Leiden or 
prothrombin variants because long-term prophylaxis to reduce the risk of recurrence offers 
similar benefits to patients with and without one of these mutations. Moreover, the EWG 
recommends against testing for asymptomatic family members because the harm of bleeding 
from prolonged use of anticoagulation by factor V Leiden or prothrombin heterozygotes 
without another risk factor might exceed the benefit of lower likelihood of venous 
thromboembolism occurrence.11 Without clear evidence of clinical utility, findings about the 
cost utility of testing are at best inconclusive.
The use of pharmacogenetic testing to guide warfarin dosing to minimize both bleeding and 
clotting appears promising based on the evidence that such testing reduces the time required 
to reach the therapeutic range, and it has received the US regulatory approval.5 A recent 
review12 identified seven cost-effectiveness analyses or CUAs of CYP2C9 and VKORC1 
genotype-guided warfarin dosing published from 2004 through to 2010. Of the four 
CUAs,12–15 three (refs. 13, 14, and 15) were cited by Phillips et al.1 All the four CUAs 
yielded ICER estimates in excess of US $50,000 per QALY, although two reported point 
estimates between US $50,000 and US $100,000 per QALY.14,15 Even though these studies 
suggest that pharmacogenetic testing for warfarin dosing might be cost effective at the 
$100,000 per QALY level, direct evidence that genetic testing to guide warfarin dosing 
reduces bleeding (a side effect) and clotting (the objective of anticoagulation) is needed to 
assess its cost effectiveness.15 Two other CUAs estimated ICERs in excess of US $150,000 
per QALY,13,16 findings that suggest that testing might not be cost effective except in higher 
risk patient subgroups.12
Phillips et al. are concerned that many genetic tests currently used in clinical medicine, as 
well as emerging tests not yet introduced, have not been formally evaluated for cost 
effectiveness. However, it is also true that most genetic tests and applications have not been 
evaluated for clinical effectiveness. It may be wise to wait for evidence of a testing 
application’s effectiveness in terms of improved patient outcomes before assessing its cost 
effectiveness. As stated by Rogowski et al.,17 if the required levels of evidence are 
undefined or excessively low, this could prematurely move technologies toward practice, 
with potentially adverse consequences for the patients and the health-care system.
Even without conclusive evidence of clinical utility from randomized trials, decision 
analytic models without costs, also known as risk–benefit models, may help to identify the 
factors that are most likely to be influential in determining net benefit to patients. Such 
models can also help in identifying the types of clinical information that are most needed for 
evidence-based decisions on clinical utility.18–20
Similarly, value of information analytic methods can help to prioritize research investments 
by calculating the potential economic value of reducing the probability of making a wrong 
decision based on currently available evidence and calculations of cost effectiveness.5,17 A 
wrong decision can entail either approving a test that has no positive effect on outcomes or 
conversely, rejecting a test the use of which would improve health outcomes. A value of 
information analysis calculates the economic gain from optimized coverage decisions 
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resulting from more accurate predictions of effectiveness and cost effectiveness. A study 
that developed value of information analyses for multiple testing strategies in cancer 
genomics found that the value of information calculations led stakeholders to appreciate the 
value of gathering new research data to determine whether a widely used genomic test 
actually provides clinical utility.21
The primary constraint in understanding the economic value of genetic testing in medicine 
may not be lack of formal economic evaluations, but rather the unmet need for reliable, 
reproducible data on clinical outcomes. Demonstrated clinical utility is the essential 
foundation of reliable cost-utility estimates.
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